Sanofi Holds Line On Aventis Merger Price; Novartis Enters Talks
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi will continue to evaluate the market reaction before deciding whether to sweeten its bid. Novartis accepts Aventis’ invitation to explore a deal; the move indicates France has expressed neutrality on an Aventis/Novartis combination.
You may also be interested in...
Sanofi-Aventis Merger Set; $65 Bil. Deal Means More Leverage With Managed Care
Sanofi-Aventis' $30 bil. pharma/vaccine business will provide bulk necessary to better negotiate discounts. Sanofi has not had much opportunity to work within U.S. managed care system, but says it will learn from Aventis.
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an added $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Sanofi-Aventis Merger Set; $65 Bil. Deal Means More Leverage With Managed Care
Sanofi-Aventis' $30 bil. pharma/vaccine business will provide bulk necessary to better negotiate discounts. Sanofi has not had much opportunity to work within U.S. managed care system, but says it will learn from Aventis.